GET DAILY SIGNALSCentene (CNC) Up +66% YTD as Medicare Advantage Nears Breakeven
Key Takeaways
- Centene (CNC) shares have traded near $68.50, up roughly 5% over the trailing 30 days, with the move reflecting broad managed-care momentum rather than a single event.
- The stock has climbed about 66% year to date, recovering sharply from 2025, when elevated medical costs forced management to withdraw its earnings guidance.
- Third-quarter 2026 adjusted EPS of $0.58 beat consensus estimates, and management raised full-year adjusted EPS guidance to above $5.20.
- Medicare Advantage is on track to reach breakeven in 2026, a year earlier than previously planned, strengthening the company's turnaround narrative.
- Medicaid enrollment declines, reimbursement-rate uncertainty, and regulatory risk remain the primary headwinds for the stock.
- For additional details on valuation and expectations, explore Centene's Price Targets, Earnings, and Forecast pages.
Where Centene Stands in the Current Market
From what I see, Centene (CNC) shares have consolidated in the upper $60s to low $70s range, hovering just below a 52-week high of $78.08 reached in early November. The stock's beta is relatively low, and its price remains well above both the 50-day and 200-day moving averages, a sign of sustained upward momentum after a volatile 2025. Sentiment toward managed care has improved broadly, with investors rewarding companies that are demonstrating better medical-cost discipline and clearer earnings visibility. Within the group, Centene has outperformed the broader S&P 500 this year while still trading at a valuation discount to larger managed-care peers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Centene Corporation (CNC) Business Overview and Competitive Position
Centene Corporation is a Fortune 50 healthcare enterprise headquartered in St. Louis, Missouri, and one of the largest managed care organizations in the United States. The company focuses primarily on government-sponsored programs, serving Medicaid, Medicare, and Affordable Care Act (ACA) Marketplace populations, along with a Commercial segment. Its scale gives it a meaningful position in publicly funded health coverage, particularly among lower-income and under-insured individuals.
Centene competes with major diversified insurers such as UnitedHealth Group (UNH) and Elevance Health (ELV). Its competitive strengths include deep state-level Medicaid relationships, a broad provider network, and a growing portfolio of specialty services spanning pharmacy, behavioral health, dental, and vision. Investors follow the stock closely because its results are tied to government reimbursement rates, enrollment trends, and regulatory policy, all of which can shift earnings meaningfully from quarter to quarter.
Recent Developments Driving CNC
The most significant recent catalyst was Centene's third-quarter 2026 earnings report. The company posted adjusted diluted EPS of $0.58, well above the roughly $0.10 consensus, on revenue of $50.65 billion that also topped estimates. Management raised full-year 2026 adjusted EPS guidance to greater than $5.20, up from a prior floor of $4.80, and lifted its revenue outlook. Executives attributed the beat to stabilizing medical-cost trends, disciplined cost management in Medicaid, and strength in Medicare and Marketplace businesses. I checked the latest signals on this using Tickeron’s AI Daily Buy/Sell Signals to confirm the momentum.
In October, Centene also announced plans to launch a National Performance-Based Gold Card Program to streamline prior authorization for qualifying outpatient services, part of a broader effort to reduce administrative friction for providers. On the analyst front, several firms raised price targets following the earnings update, including Barclays, Truist, J.P. Morgan, and Wells Fargo, with consensus estimates pointing to a price target near the mid-$70s.
A late-period surge in the stock also followed the U.S. midterm elections, as investors viewed the outcome as reducing policy uncertainty for government-backed health programs. The stock gained sharply in a single session before giving back part of that move, underscoring how sensitive managed-care valuations remain to political and regulatory developments.
2026 Outlook and What Investors Should Watch
Looking ahead, Centene's investment case hinges on whether it can sustain margin recovery while managing enrollment and policy headwinds. Medicaid membership, which ended the third quarter at roughly 11.9 million, is expected to decline further as states implement eligibility reviews and work requirements, so investors should watch how rate actions offset those losses. The trajectory of the Medicare Advantage business toward breakeven, and any confirmation that Marketplace margins remain at the top of guidance, will also be key signals.
Regulatory and political developments remain central. Changes to Medicaid funding, ACA subsidies, and Part D prescription drug rules can materially affect Centene's profitability. Management has indicated it will provide formal 2027 guidance in February, when enrollment results and state rate decisions should offer clearer visibility. While analysts generally maintain a constructive view, the company's dependence on government-funded programs means reimbursement adequacy, medical-cost trends, and competitive contract reprocurements will continue to drive sentiment into 2026 and beyond. I'm watching this closely as the February update approaches.
Exploring AI-Driven Trading Approaches
In my own research process, I often look at Tickeron's Trending AI Robots to see which automated strategies are gaining traction across thousands of tickers. The page curates top-performing bots by strategy and performance metrics, offering a practical way to compare systematic signals alongside fundamental analysis. This adds another layer of data-driven perspective without replacing core research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CNC in upward trend: price rose above 50-day moving average on October 09, 2026
CNC moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 56 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CNC as a result. In 56 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The 10-day moving average for CNC crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +14.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNC advanced for three days, in 186 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 132 of 213 cases where CNC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for CNC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 18 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 60 cases where CNC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for CNC turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 30 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
CNC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. CNC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CNC's P/B Ratio (1.527) is slightly lower than the industry average of (3.520). P/E Ratio (-6.751) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (0.754) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (0.569).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a multi-line healthcare enterprise
Industry ManagedHealthCare
Advertisement